Izumi Techno is a retail company that provides cleaning, repairs, and renewals services.

Longeviti Neuro Solutions LLC operates as a neuro-technology company that focuses on brain surgery solutions. It offers a platform for novel medical devices. The company was founded by Chad Gordon and Jesse Christopher in 2016 and is headquartered in Hunt Valley, MD.

CSL Behring AG, part of CSL Ltd., is a company headquartered in Bern, Switzerland. The firm develops biological products.

Develops and manufactures drugs related to immunology, neurobiology and oncology

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain. It addresses the unmet needs in the treatment of chronic neuropathological conditions. For many neurologic conditions, there are identified molecular targets, but the blood-brain barrier prevents drugs from addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. The company is transforming disease-modifying therapies for rare and orphan disorders through Advanced Precision Delivery Platforms.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

Wuhan Zhongke Keli Photoelectric Technology Co., Ltd., established on 2007-07-20, The scope of business includes two types of:6824Medical laser equipment,6825Medical high-frequency equipment,6826Production of physical therapy and rehabilitation equipment.(Operate within the approved scope and time limit with the license);Optoelectronic product development,Production,Sales,Install,debugging,Repair and after-sales service;laser products,Research and development of mechanical products,Production,Sales,Install,debugging,Repair and after-sales service;software development,Production,Sales,Install,debugging,Repair and after-sales service;Computer system integration and technical services;control system,Instrumentation,Automation technology research and development,Production,Sales,Install,debugging,Repair and after-sales service;Import and export,Technology Import and Export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. is a company headquartered in Calgary, AB, Canada, that develops pharmaceutical products. The firm was founded by Susan Dana Jones. Transition Therapeutics, Inc., a subsidiary of OPKO Health, Inc. since September 2016, acquired Waratah Pharmaceuticals, Inc. on January 28, 2002 for $15.46 million.

Synedgen is a bio-pharmaceutical company committed to developing novel therapies and products that reduce infection and inflammation at dermal, oral, mucosal, and ophthalmic surfaces. It uses a comprehensive approach using novel polysaccharide derivatives that minimize or treat infections by targeting sites where bacteria enter the human body and encourage healing after infection or acute and chronic damage. Synedgen was formed in 2009 through the merger of BioSTAR West (Claremont, California) and Hawaii Chitopure (Honolulu, Hawaii). BioSTAR West was founded in 2005 to generate research and development expertise in biopolymer processing and polymer interactions with mammalian cells and bacteria. This research led to chemical modifications of a natural biopolymer and examination of the molecular interactions of these derivatives with tissue and bacterial pathogens. Synedgen is managed by an experienced team of scientists and business executives with strengths in innovation, synthetic and analytical chemistry, microbiological research, clinical research, regulatory process, product development, corporate partnering, FDA approvals, and successful non-dilutive fundraising.

Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distributing safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Every week in America, more than one million Par prescriptions are dispensed. In return for the trust that is placed in us, we are committed to providing products of uncompromising quality with the highest levels of service. In fulfilling this mission, we deliver value to our customers and the physicians and patients that rely on us. Today, the company’s sales place it among the top 5 largest generic pharmaceutical companies in the United States.

ExploraMed is a venture-backed medical technology incubation company. The company's medical technology incubator is used to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures, and businesses. It is dedicated to the identification, creation, and development of new medical devices which match certain key fundamental criteria and add capital, intellectual property, and expertise in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development that enable clinicians to meet the unmet health needs of patients around the world.

Wuhan Zhongzhen Intelligent Technology Co., Ltd., established on 2019-12-10, The scope of business includes the research and development of third-class medical devices and equipment,Production(Operate within the approved period with the license);software,Optoelectronics,laser products,General Machinery,Instrumentation,Research and development of industrial automation equipment,Production,Sales,Install,debugging,Maintenance and after-sales service;Computer System Integration Services;Import and export,Technology Import and Export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.